MANNKIND CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.
Cantor Fitzgerald maintained an Overweight rating on MannKind with an $8 price target, suggesting a 158.9% upside from the Oct 19 close of $3.09. The firm cited MannKind's strong product pipeline and positive market response to recent product launches.
Chardan Capital initiated coverage of MannKind with a Buy rating and $10 price target, implying a 228.9% upside from the Oct 16 close. The analyst highlights MannKind's strong pipeline, including Furoscix, Afrezza, and MNKD-201, and positive market dynamics for these products.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning MNKD (MANNKIND CORP). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent MNKD coverage spans financial news, technology and regulation.
In the last 30 days, MNKD insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($128K). The most active reporter was Binder Steven B. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive pipeline and product launch news could lift MNKD as investors price in future growth.
Analyst upgrade with a higher price target may attract buying interest.
Analyst initiation and high price target likely attract buying interest.
Positive trial data may boost investor confidence in MNKD's recently approved product.
Positive clinical data may boost expectations for product adoption and revenue.
AlphAI scores every news story that mentions MNKD with an AI model for sentiment and relevance, and aggregates insider trades from MANNKIND CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.
2 min readCantor Fitzgerald maintained an Overweight rating on MannKind with an $8 price target, suggesting a 158.9% upside from the Oct 19 close of $3.09. The firm cited MannKind's strong product pipeline and positive market response to recent product launches.
1 min readChardan Capital initiated coverage of MannKind with a Buy rating and $10 price target, implying a 228.9% upside from the Oct 16 close. The analyst highlights MannKind's strong pipeline, including Furoscix, Afrezza, and MNKD-201, and positive market dynamics for these products.
1 min readMannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.
2 min readMannKind (MNKD) presented data at HFSA 2026 showing Furoscix ReadyFlow's subcutaneous injection achieved IV-equivalent exposure and diuretic effect. The study demonstrated flexibility in injection sites, including the thigh and arm. This follows recent FDA approval and supports the company's clinical equivalence claims.
1 min readMannKind (MNKD) partnered with Rose Pharma to develop ROSE-010, an inhaled weight-loss drug. The deal gives MannKind equity, royalties, and a board seat. ROSE-010 has completed Phase 2a trials showing weight loss and pain relief. MannKind reported Q2 revenue of $109.4M, up 43% YoY, with recent FDA approvals and positive trial data.
2 min readMannKind (MNKD) and Rose Pharma agreed to develop ROSE-010, an inhaled GLP-1 receptor agonist for weight management. MannKind licenses its Technosphere tech, gets equity and royalties. ROSE-010 showed promise in weight loss and IBS pain relief trials. MNKD stock closed at $4.16, up 2.46%.
1 min readMannKind (MNKD) announced a global licensing deal with Rose Pharma for an inhaled GLP-1 therapy. The company's P/S ratio is 3.29, below historical and industry medians. GF Value™ suggests a 44.2% undervaluation, but financial risks remain high. Insiders and gurus show cautious activity.
3 min readMannKind (MNKD) partners with Rose Pharma to develop ROSE-010, an inhaled weight-loss drug using Technosphere technology. MannKind will receive an equity stake and potential royalties. ROSE-010 showed weight loss and reduced calorie intake in prior studies. MNKD shares rose 1.7% in pre-market trading.
2 min readMannKind (MNKD) shares rose 5% after FDA approved Afrezza for diabetes treatment in children aged 6+. The approval follows Phase 3 trial data showing Afrezza's noninferiority to injections in HbA1c changes, with higher patient satisfaction and less weight gain. Afrezza uses Technosphere tech for rapid insulin delivery via inhalation.
2 min read
